Medical Device News Magazine

BIOTRONIK: BIO-LIBRA Initial Interim Analysis Results Demonstrate Higher Probability of Ventricular Tachyarrhythmias or Mortality in Men than Women

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

In conjunction with BIOTRONIK, Valentina Kutyifa, MD, PhD, presented the first interim analysis results from the BIO-LIBRA study in a poster contribution at the American College of Cardiology’s 71st Annual Scientific Session.

Women have been traditionally underrepresented in clinical trials conducted in patients with implanted medical devices, contributing to only 20-25 percent of the study population, significantly limiting our understanding of sex-specific outcomes. In a quest to close this gap, Valentina Kutyifa, MD, PhD, Jeanne Poole, MD, and BIOTRONIK designed and conducted the BIO-LIBRA study to ensure that men and women are equally represented.

The results presented today show significant differences in one-year ventricular tachyarrhythmia or death rates by sex in patients with non-ischemic cardiomyopathy with an ICD or CRT-D. The one-year probability of VT/VF or death was 7% in women and 13% in men, higher than expected by the study investigators.

View BIO-LIBRA One-Year Results Here

The BIO-LIBRA study, launched in 2019, is a multi-center, prospective, observational registry study designed to improve our understanding of outcomes in men and women with non-ischemic cardiomyopathy and an implanted ICD or CRT-D, while also observing demographic differences. The study has enrolled 1,000 patients with non-ischemic cardiomyopathy with an ICD or CRT-D at 48 centers through the United States. The primary endpoint of BIO-LIBRA is ventricular tachyarrhythmia or death.

BIO-LIBRA has been designed to specifically encourage a minimum of 40% female enrollment as a way of addressing the limited contemporary data available on sex-specific outcomes as related to this type of treatment.

The results announced today include the study’s initial 500 patients with a completed 1 year of follow-up. This population is 47% female, which exceeds stated goals, and 37% of the subjects are non-white, truly representing a diverse population more representative of the real world.

Further results will be presented as the study progresses.

BIOTRONIK notes Kutyifa V presented at ACC.22 – Poster Contribution April 4, 2022, Session 1558 – Heart Failure and Cardiomyopathies

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”